PURPOSE: To determine the oncologic benefit or otherwise of local treatment of the prostate in patients with primary metastatic prostate cancer. METHODS: A review of the literature was performed in April 2014 using the Medline/PubMed database. Studies were identified using the search terms "prostate cancer," "metastatic," "metastasis," "high risk," "radiation therapy," "radiotherapy" and "prostatectomy" from 1990 until April, 2014. Articles were also identified through searches of references of these articles. RESULTS: Retrospective series and population-based data suggest that the use of local treatment of the prostate in patients with primary metastatic prostate cancer may improve cancer-specific survival and overall survival compared with treating these patients with androgen deprivation therapy alone. The clinical outcome in metastatic prostate cancer is largely determined by the extent of lymph node involvement and overall metastatic burden. Contemporary data are lacking to recommend one alternative of local therapy (radiotherapy or radical prostatectomy) over the other. The primary limitation of this literature review is the lack of published randomized trial assessing the role of local treatment in addition to systemic therapy. CONCLUSIONS: Local treatment appears to improve oncologic outcomes in metastatic prostate cancer patients. Nevertheless, due to the lack of high-quality evidence, its role needs to be confirmed in future prospective trials. The selection of ideal candidates and optimal treatment alternative (radiotherapy, radical prostatectomy or other) warrants further investigation.
PURPOSE: To determine the oncologic benefit or otherwise of local treatment of the prostate in patients with primary metastatic prostate cancer. METHODS: A review of the literature was performed in April 2014 using the Medline/PubMed database. Studies were identified using the search terms "prostate cancer," "metastatic," "metastasis," "high risk," "radiation therapy," "radiotherapy" and "prostatectomy" from 1990 until April, 2014. Articles were also identified through searches of references of these articles. RESULTS: Retrospective series and population-based data suggest that the use of local treatment of the prostate in patients with primary metastatic prostate cancer may improve cancer-specific survival and overall survival compared with treating these patients with androgen deprivation therapy alone. The clinical outcome in metastatic prostate cancer is largely determined by the extent of lymph node involvement and overall metastatic burden. Contemporary data are lacking to recommend one alternative of local therapy (radiotherapy or radical prostatectomy) over the other. The primary limitation of this literature review is the lack of published randomized trial assessing the role of local treatment in addition to systemic therapy. CONCLUSIONS: Local treatment appears to improve oncologic outcomes in metastatic prostate cancerpatients. Nevertheless, due to the lack of high-quality evidence, its role needs to be confirmed in future prospective trials. The selection of ideal candidates and optimal treatment alternative (radiotherapy, radical prostatectomy or other) warrants further investigation.
Authors: R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford Journal: N Engl J Med Date: 2001-12-06 Impact factor: 91.245
Authors: Stephen A Boorjian; R Jeffrey Karnes; Rosalia Viterbo; Laureano J Rangel; Eric J Bergstralh; Eric M Horwitz; Michael L Blute; Mark K Buyyounouski Journal: Cancer Date: 2011-01-10 Impact factor: 6.860
Authors: Firas Abdollah; R Jeffrey Karnes; Nazareno Suardi; Cesare Cozzarini; Giorgio Gandaglia; Nicola Fossati; Marco Bianchi; Stephen A Boorjian; Maxine Sun; Pierre I Karakiewicz; Francesco Montorsi; Alberto Briganti Journal: Eur Urol Date: 2013-09-27 Impact factor: 20.096
Authors: Fritz H Schröder; Karl-Heinz Kurth; Sophie D Fossa; Wytse Hoekstra; Peter P Karthaus; Linda De Prijck; Laurence Collette Journal: Eur Urol Date: 2008-09-17 Impact factor: 20.096
Authors: Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså Journal: Lancet Date: 2008-12-16 Impact factor: 79.321
Authors: Georgios Gakis; Stephen A Boorjian; Alberto Briganti; Steven Joniau; Guram Karazanashvili; R Jeffrey Karnes; Agostino Mattei; Shahrokh F Shariat; Arnulf Stenzl; Manfred Wirth; Christian G Stief Journal: Eur Urol Date: 2013-05-22 Impact factor: 20.096
Authors: Padraig Warde; Malcolm Mason; Keyue Ding; Peter Kirkbride; Michael Brundage; Richard Cowan; Mary Gospodarowicz; Karen Sanders; Edmund Kostashuk; Greg Swanson; Jim Barber; Andrea Hiltz; Mahesh K B Parmar; Jinka Sathya; John Anderson; Charles Hayter; John Hetherington; Matthew R Sydes; Wendy Parulekar Journal: Lancet Date: 2011-11-02 Impact factor: 79.321
Authors: Isaac Yi Kim; Antonina Mitrofanova; Sukanya Panja; Joshua Sterling; Arnav Srivastava; Juliana Kim; Sinae Kim; Eric A Singer; Thomas L Jang; Saum Ghodoussipour; Biren Saraiya; Tina Mayer; Hatem E Sabaawy; Bertram Yuh; Seok Soo Byun; Wun-Jae Kim; Shigeo Horie Journal: Prostate Int Date: 2022-03-09